Skip to main content
. 2021 Jul 30;24(4):689. doi: 10.3892/mmr.2021.12330

Figure 3.

Figure 3.

miR-351-5p antagomir inhibits LPS-induced inflammation and NLRP3 inflammasome in the lungs. (A) Relative mRNA expression levels of proinflammatory cytokines IL-1β, IL-6 and TNF-α in the lungs (n=6). (B) TNF-α levels in the lungs and BALFs measured by ELISA (n=6). (C) Relative mRNA expression levels of NLRP3, ASC and pro-caspase-1 in the lungs (n=6). (D) Representative blots and (E) quantification of NLRP3 and caspase-1 p10 protein expression levels determined by western blot analysis (n=6). (F) Relative caspase-1 activity (n=6). (G) IL-1β and IL-18 levels in the lungs measured by ELISA (n=6). (H) Total cells, macrophages and neutrophils in BLAFs were counted (n=6). (I) MPO activity in the lungs with or without miR-351-5p antagomir treatment upon LPS challenge (n=6). All data are expressed as mean ± SD. *P<0.05 with comparisons shown by lines. miR, microRNA; LPS, lipopolysaccharide; NLRP3, NACHT, LRR and PYD domain-containing protein 3; BALF, bronchoalveolar lavage fluid; ASC, apoptosis-associated speck-like protein containing a CARD; MPO, myeloperoxidase; NC, negative control.